MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Definitive Material Agreement.
On November 30, 2018, the Company entered into a Third Amendment to Forbearance Agreement with GPB DEBT HOLDING II, LLC (“Lender”), whereby the Lender agreed to forbear its exercise of registration rights to Section 4.9 of the Securities Purchase Agreement dated September 26, 2017 (“SPA”), until January 31, 2019.
Item 5.02 Departure of Directors or Principal Officers, Election of Directors, Appointment of Principal Officers.
On November 30, 2018, the Board of Directors (the “Board”) of MEDITE Cancer Diagnostics, Inc. (the “Company”) accepted the resignation of Stephen Von Rump as Chief Strategy Officer of the Company, effective immediately.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
10.1 |
Form of Third Amendment to Forbearance Agreement |
|
99.1 |
Resignation Letter of Stephen Von Rump |
Medite Cancer Diagnostics, Inc. ExhibitEX-10.1 2 ex10-1.htm FORM OF THIRD AMENDMENT TO FORBEARANCE AGREEMENT 8-K EXHIBIT 10.1 Form of Third Amendment to Forbearance Agreement THIRD AMENDMENT TO FORBEARANCE AGREEMENT This THIRD AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of November 30,…To view the full exhibit click here
About MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT)
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.
